Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be enrolled before treatment begins.~* Patients must be ≥ 12 months and \< 22 years of age at the time of diagnosis.~* The target tumors are primary brain non-metastatic (M0) ependymomas tumors. Patients must have histologic verification of an ependymoma at diagnosis. Patients with the following world health organization (WHO) diagnoses will be eligible for this study:Ependymoma (Subtypes: cellular, papillary, clear cell and tanycytic) and Anaplastic Ependymoma~* Life expectancy of ≥ 8 weeks.~* Newly diagnosed ependymoma and must not have had any prior chemotherapy or radiotherapy.~* All patients must have:~  * A pre-operative MRI scan of the brain with and without contrast. NOTE: CT scans are NOT sufficient for study eligibility since radiation therapy planning and responses will be based on MRI scans only.~ * Post-operative head MRI scan with and without contrast (preferably within 72 hours post-operatively).~ * Spinal MRI (T-1 weighted imaging with and without gadolinium) is required within 28 days of surgery if done post-operatively and within 14 days of surgery if done pre-operatively. For posterior fossa tumors, pre-operative MRI scans are preferred because surgically induced inflammation/blood can be difficult to distinguish from tumor.~ * Lumbar CSF cytology examination obtained between 7 and 31 days following surgery.~ * Adequate bone marrow function, defined as:~ * Peripheral absolute neutrophil count (ANC) \>1500/μL~ * Platelet count ≥ 100,000/μL (transfusion independent)~ * Hemoglobin ≥ 10.0 gm/dl (may receive RBC transfusions)~ * Adequate renal function defined as:~ * Serum creatinine \< 1.5 times the upper limit of normal based on the patient's age, or creatinine clearance greater than 60 ml/min/1.73 m² corrected for age and body surface area.~ * Adequate liver function defined as:~ * Total bilirubin \<1.5 x the institutional normal~ * SGOT (AST) or SGPT (ALT) \<2.5 x institutional normals.~* Patients must begin chemoradiotherapy within 56 days of definitive surgery.~* All patients and/or their parents or legal guardians must sign a written informed consent~* Patients must provide assent as per local IRB guidelines (if applicable).~* Patients and/or their families must consent to the mandatory biology studies, including serum Survivin levels, CSF Survivin levels, paraffin-embedded tissue and fresh-frozen tissue when available.~* Karnofsky/Lansky scoring greater than 50.~* Corticosteroid supportive care is permissible at the clinician's discretion prior to and during chemo-radiotherapy.~* Anti-seizure medication support is permitted as necessary and at the treating physician's discretion.~Exclusion:~* Prior chemotherapy or prior radiotherapy~* Patients who are pregnant or breast feeding, or patients (male or female) not employing adequate contraception. Acceptable means of birth control include IUD, oral contraceptive, subdermal implant, a condom with a contraceptive sponge or suppository or abstinence.~* Patients who are unable to undergo MR imaging~* Patients with evidence of metastatic disease on spine MRI or CSF sampling~* Patients with post-operative residual tumor \> 0.5 cm, unless a repeat surgery is performed making the residual tumor less than 1.5 cm². Note: Timing for enrollment and initiation of therapy will begin after second surgery if a repeat surgery is performed.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Carboplatin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).